COTELLIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cotellic, and what generic alternatives are available?
Cotellic is a drug marketed by Genentech Inc and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and eighty-four patent family members in forty-three countries.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this compound. Additional details are available on the cobimetinib fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Cotellic
Cotellic was eligible for patent challenges on November 10, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 30, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COTELLIC?
- What are the global sales for COTELLIC?
- What is Average Wholesale Price for COTELLIC?
Summary for COTELLIC
| International Patents: | 184 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 10 |
| Clinical Trials: | 35 |
| Patent Applications: | 1 |
| Drug Prices: | Drug price information for COTELLIC |
| What excipients (inactive ingredients) are in COTELLIC? | COTELLIC excipients list |
| DailyMed Link: | COTELLIC at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for COTELLIC
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for COTELLIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Manchester | Phase 2/Phase 3 |
| Hoffmann-La Roche | Phase 2/Phase 3 |
| University of Birmingham | Phase 2/Phase 3 |
Pharmacology for COTELLIC
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors |
US Patents and Regulatory Information for COTELLIC
COTELLIC is protected by seven US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of COTELLIC is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting COTELLIC
Immediate-release tablets containing combimetinib and methods of making and using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combination therapies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AS A SINGLE AGENT FOR THE TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
Azetidines as MEK inhibitors for the treatment of proliferative diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Azetidines as MEK inhibitors for the treatment of proliferative diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting COTELLIC
TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
Exclusivity Expiration: ⤷ Sign Up
INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY GO29665
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for COTELLIC
When does loss-of-exclusivity occur for COTELLIC?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 5483
Patent: SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3-HIDROXI-3-(PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 16288209
Patent: Crystalline fumarate salt of (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) (3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl)-methanone
Estimated Expiration: ⤷ Sign Up
Patent: 21200202
Patent: CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017028516
Patent: sal de fumarato cristalino de (s)-[3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il) azetidin-1-il]-metanona
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 90222
Patent: SEL CRISTALLIN DE FUMARATE DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDIN-2-YL)AZETIDIN-1-YL]-METHANONE (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 17003475
Patent: Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
Estimated Expiration: ⤷ Sign Up
China
Patent: 7810183
Estimated Expiration: ⤷ Sign Up
Patent: 8290395
Patent: 结晶反丁烯二酸盐 (Crystalline fumarate salts)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 18000086
Patent: Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 180056
Patent: SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL] [3-HIDROXI-3-(PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 17264
Patent: SEL CRISTALLIN DE FUMARATE DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHÉNYLAMINO)PHÉNYL][3-HYDROXY-3-(PIPÉRIDIN-2-YL)AZÉTIDIN-1-YL]-MÉTHANONE (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 52433
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6423
Patent: מלח פומראט גבישי של (s (-[4,3-דיפלואורו-2-(2-פלואורו-4-יודופנילאמינו)פניל] [3-הידרוקסי-3-(פיפרידין-2-איל)אזטידין-1-איל]-מתאנון (Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone)
Estimated Expiration: ⤷ Sign Up
Patent: 5052
Patent: מלח פומראט גבישי של (s)-[4,3-דיפלואורו-2-(2-פלואורו-4-יודופנילאמינו)פניל] [3-הידרוקסי-3-(פיפרידין-2-איל)אזטידין-1-איל]-מתאנון (Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 38950
Estimated Expiration: ⤷ Sign Up
Patent: 18519318
Patent: （Ｓ）−［３，４−ジフルオロ−２−（２−フルオロ−４−ヨードフェニルアミノ）フェニル］［３−ヒドロキシ−３−（ピペリジン−２−イル」）アゼチジン−１−イル］−メタノンの結晶性フマル酸塩
Estimated Expiration: ⤷ Sign Up
Patent: 21035967
Patent: （Ｓ）−［３，４−ジフルオロ−２−（２−フルオロ−４−ヨードフェニルアミノ）フェニル］［３−ヒドロキシ−３−（ピペリジン−２−イル）アゼチジン−１−イル］−メタノンの結晶性フマル酸塩 (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE)
Estimated Expiration: ⤷ Sign Up
Patent: 23025000
Patent: （Ｓ）－［３，４－ジフルオロ－２－（２－フルオロ－４－ヨードフェニルアミノ）フェニル］［３－ヒドロキシ－３－（ピペリジン－２－イル）アゼチジン－１－イル］－メタノンの結晶性フマル酸塩
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 2545
Patent: CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17017037
Patent: SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODO FENILAMINO) FENIL][3-HIDROXI-3-(PIPERIDIN-2-IL]AZETIDIN-1-IL]-META NONA. (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODO PHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 301
Patent: SEL CRISTALLIN DE FUMARATE DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHÉNYLAMINO)PHÉNYL][3-HYDROXY-3-(PIPÉRIDIN-2-YL)AZÉTIDIN-1-YL]-MÉTHANONE
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 180692
Patent: SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3-HIDROXI-3-(PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 017502414
Patent: CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 62181
Patent: КРИСТАЛЛИЧЕСКАЯ ФУМАРАТНАЯ СОЛЬ (S)-[3,4-ДИФТОР-2-(2-ФТОР-4-ЙОДФЕНИЛАМИНО)ФЕНИЛ][3-ГИДРОКСИ-3-(ПИПЕРИДИН-2-ИЛ)АЗЕТИДИН-1-ИЛ]МЕТАНОНА (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDINE-2-YL)AZETIDINE-1-YL]METHANONE)
Estimated Expiration: ⤷ Sign Up
Patent: 18103172
Patent: КРИСТАЛЛИЧЕСКАЯ ФУМАРАТНАЯ СОЛЬ (S)-[3,4-ДИФТОР-2-(2-ФТОР-4-ЙОДФЕНИЛАМИНО)ФЕНИЛ][3-ГИДРОКСИ-3-(ПИПЕРИДИН-2-ИЛ)АЗЕТИДИН-1-ИЛ]МЕТАНОНА
Estimated Expiration: ⤷ Sign Up
Patent: 21132394
Patent: КРИСТАЛЛИЧЕСКАЯ ФУМАРАТНАЯ СОЛЬ (S)-[3,4-ДИФТОР-2-(2-ФТОР-4-ЙОДФЕНИЛАМИНО)ФЕНИЛ][3-ГИДРОКСИ-3-(ПИПЕРИДИН-2-ИЛ)АЗЕТИДИН-1-ИЛ]МЕТАНОНА
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 202105196Y
Patent: CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1708760
Patent: CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2695324
Estimated Expiration: ⤷ Sign Up
Patent: 180021775
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 10556
Estimated Expiration: ⤷ Sign Up
Patent: 75187
Estimated Expiration: ⤷ Sign Up
Patent: 1718535
Patent: Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Estimated Expiration: ⤷ Sign Up
Patent: 2108568
Patent: Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4728
Patent: КРИСТАЛІЧНА ФУМАРАТНА СІЛЬ (S)-[3,4-ДИФТОР-2-(2-ФТОР-4-ЙОДФЕНІЛАМІНО)ФЕНІЛ][3-ГІДРОКСИ-3-(ПІПЕРИДИН-2-ІЛ)АЗЕТИДИН-1-ІЛ]МЕТАНОНУ (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering COTELLIC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ukraine | 124728 | КРИСТАЛІЧНА ФУМАРАТНА СІЛЬ (S)-[3,4-ДИФТОР-2-(2-ФТОР-4-ЙОДФЕНІЛАМІНО)ФЕНІЛ][3-ГІДРОКСИ-3-(ПІПЕРИДИН-2-ІЛ)АЗЕТИДИН-1-ІЛ]МЕТАНОНУ (CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE) | ⤷ Sign Up |
| Malaysia | 162174 | AZETIDINES MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ⤷ Sign Up |
| Russian Federation | 2021132394 | КРИСТАЛЛИЧЕСКАЯ ФУМАРАТНАЯ СОЛЬ (S)-[3,4-ДИФТОР-2-(2-ФТОР-4-ЙОДФЕНИЛАМИНО)ФЕНИЛ][3-ГИДРОКСИ-3-(ПИПЕРИДИН-2-ИЛ)АЗЕТИДИН-1-ИЛ]МЕТАНОНА | ⤷ Sign Up |
| Croatia | P20191533 | ⤷ Sign Up | |
| Eurasian Patent Organization | 019983 | ИНГИБИТОРЫ MEK И СПОСОБЫ ИХ ПРИМЕНЕНИЯ (MEK INHIBITORS AND METHODS OF USING SAME) | ⤷ Sign Up |
| European Patent Office | 1934174 | AZETIDINES EN TANT QU'INHIBITEURS DE MEK ET LEUR UTILISATION POUR LE TRAITEMENT DES MALADIES PROLIFERATIVES (AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COTELLIC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1934174 | 22/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB ALS EIN EINZELNES STEREOISOMER ODER ALS EINE MISCHUNG VON STEREOISOMEREN DAVON, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE UND SOLVATE, INSBESONDERE COBIMETINIB HEMIFUMARAT; REGISTRATION NO/DATE: EU/1/15/1048 (MITTEILUNG) 20151124 |
| 1934174 | SPC/GB16/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB, INCLUDING A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR COBIMETINIB HEMIFUMARATE; REGISTERED: UK EU/1/15/1048/001(NI) 20151124; UK PLGB 00031/0849 20151124 |
| 1934174 | C201630028 | Spain | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1048; DATE OF AUTHORISATION: 20151120; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1048; DATE OF FIRST AUTHORISATION IN EEA: 20151120 |
| 1934174 | 93078 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB, EVENTUELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE, Y COMPRIS LES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER HEMIFUMARATE DE COBIMETINIB; FIRST REGISTRATION DATE: 20151124 |
| 1934174 | 650 | Finland | ⤷ Sign Up | |
| 1934174 | CR 2016 00021 | Denmark | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB OG FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER DERAF, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
